Premium
Tilorone activates NK cells and cytotoxic lymphocytes that kill HLA‐negative tumor cells
Author(s) -
Sharapova Tatia.,
Romanova Elena A.,
Sashchenko Lidia P.,
Yashin Denis V.
Publication year - 2019
Publication title -
iubmb life
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.132
H-Index - 113
eISSN - 1521-6551
pISSN - 1521-6543
DOI - 10.1002/iub.1985
Subject(s) - cytotoxic t cell , immune system , cd8 , acquired immune system , biology , innate immune system , immunology , peripheral blood mononuclear cell , immunity , in vitro , biochemistry
Tilorone hydrochloride, a low‐molecular‐weight synthetic compound, induces interferon production and has been reported to have both antiviral and antitumor activities. Here, we have demonstrated the ability of tilorone to activate NK cells and specific subpopulations of cytotoxic CD4+ and CD8+ T lymphocytes that recognize immune‐evasive tumor cells and kill them via the FasL–Fas interaction. We have also performed a comparative analysis of characteristics between lymphocytes activated in the fraction of human peripheral blood mononuclear cells (PBMCs) upon treatment with different stimulants of the immune response: tilorone, innate immunity protein Tag7, and cytokine IL‐2, a regulator of adaptive immunity. The results show that all the three stimulants, regardless of their nature, activate lymphocytes that are identical with respect to the spectrum of target cells, phenotype, and mechanism of cytotoxic action However, these stimulants induce different mechanisms of lymphocyte activation at early stages of the immune response. © 2018 IUBMB Life, 71(3):376–384, 2019